Xencor To Present Phase 1 Data On XmAb(R)2513 Antibody For Lymphomas At The American Society Of Clinical Oncology Annual Meeting

Main Category: Lymphoma / Leukemia / Myeloma
Also Included In: Cancer / Oncology;  Clinical Trials / Drug Trials
Article Date: 19 May 2009 - 4:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Xencor, Inc., an antibody discovery and development company, will present data from its Phase 1 study of XmAb®2513, an anti-CD30 Fc engineered humanized monoclonal antibody for the treatment of patients with relapsed Hodgkin lymphoma and anaplastic large cell lymphoma, on June 1 in a poster session at the American Society of Clinical Oncology Annual Meeting being held at the Orange County Convention Center in Orlando, Florida.

Poster Information

Date: Monday, June 1, 2009
Poster Session: 2:00 - 6:00 PM (Level 2, W240A)
Poster Discussion: 5:00 - 6:00 PM (Level 2, West Hall F1)
Abstract: #8531
Title: "Phase 1 study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: safety, pharmacokinetics (PK), immunogenicity and efficacy"

About XmAb2513

Xencor's lead candidate, XmAb®2513, entered clinical development in 2008 for the treatment of relapsed Hodgkin lymphoma and T cell lymphomas. XmAb®2513 is a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of a number of tumor cell types. XmAb®2513 has been engineered to contain an XmAb® Fc domain to greatly increase its cytotoxic potency. XmAb®2513 shows superior activity in recruiting primary human immune cells to kill tumor cells in in vitro models and is active in blocking tumor growth in rodent models. XmAb®2513 was humanized with Xencor's XmAb® Fv technology and was well-tolerated in primate models. XmAb®2513 is readily manufactured using standard monoclonal antibody production methods.

Source
Xencor